Syngene Builds Play In 'Exciting' ADCs Space Amid Strong Q2

The newly listed Indian contract research organization (CRO) Syngene International Ltd reported robust second quarter growth, with the top brass also outlining the firm's intent to partake in "exciting" areas such as antibody-drug conjugates (ADCs).

More from India

More from Focus On Asia